NEW YORK (GenomeWeb News) – Epigenomics today reported that its first-quarter revenues increased 36 percent due primarily to milestone payments received from Abbott and new collaborations, and its net loss dropped 16 percent year over year.

The German molecular diagnostics firm reported total revenues of €1.24 million (US$1.7 million), up 36 percent from €920,000 for the first quarter of 2008. Its diagnostics business accounted for 70 percent of its total revenue, while its biomarker service revenue accounted for 30 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.